Evaluation of apoptosis in cytologic specimens

Diagnostic Cytopathology

Volumn 38, Issue 9, 2010, Pages 685-697

  Shtilbans, Viktor ^a   Wu, Maoxin ^b   Burstein, David E ^b  

^a Genzyme Genetics   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; bcl 2; Cytopathology; p53; Surviving; TRAIL; XIAP

Indexed keywords

FAS LIGAND; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CONFOCAL LASER MICROSCOPY; CYTOLOGY; DNA FRAGMENTATION; GENE SEQUENCE; HUMAN; IMMUNOCYTOCHEMISTRY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE TYPES;

ANIMALS; APOPTOSIS; CYTOLOGICAL TECHNIQUES; HUMANS; ORGAN SPECIFICITY; SPECIMEN HANDLING;

EID: 77957354094     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21313     Document Type: Review

References (118)

1. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-163. (Pubitemid 41351311)
2. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23:3175-3185.
3. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
4. Saraste A. Morphologic criteria and detection of apoptosis. Herz 1999;24:189-195.
5. Allen RT, Hunter WJ, III, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods 1997;37:215-228.
6. Meulmeester E, Jochemsen AG. p53: A guide to apoptosis. Curr Cancer Drug Targets 2008;8:87-97.
7. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097.
8. Dowell SP, Lane DP, Hall PA. The immunocytochemical detection of p53 protein in cytological specimens: technical considerations. Cytopathology 1994;5:76-81.
9. Pelengaris S, Khan M, Evan G. c-MYC: More than just a matter of life and death. Nat Rev Cancer 2002;2:764-776. (Pubitemid 37328911)
10. Zhivotosky B, Orrenius S. Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria. Curr Protoc Cell Biol 2001;18:183.
11. Sasano H, Date F, Itakura Y, Goukon Y, Nishihira T, Nagura H. Confocal laser scanning microscopy in cytopathology. Mod Pathol 1993;6:625-629.
12. Huerta S, Goulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res 2007;139:143-156.
13. Pantelidis P, Santilli G, Knight RA. Sequential identification of apoptotic and necrotic cells on individual cytospin preparations. J Immunol Methods 1998;214:209-212. (Pubitemid 28335552)
14. Sasano H, Yamaki H, Nagura H. Detection of apoptotic cells in cytology specimens: An application of TdT-mediated dUTP-biotin nick end labeling to cell smears. Diagn Cytopathol 1998;18:398-402.
15. Okuyama T, Matsuo S, Nagamachi D, et al. Freeze-drying method for stable preservation in cellular specimens for the detection of apoptotic cells. Diagn Cytopathol 2000;22:254-255.
16. Doonan F, Cotter TG. Morphological assessment of apoptosis. Methods 2008;44:200-204.
17. Kontzoglou K, Moulakakis KG, Konofaos P, Kyriazi M, Kyroudes A, Karakitsos P. The role of liquid-based cytology in the investigation of breast lesions using fine-needle aspiration: A cytohistopathological evaluation. J Surg Oncol 2005;89:75-78.
18. Ryu HS, Chang KH, Chang SJ, Kim MS, Joo HJ, Oh KS. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer 2000;10:417-424.
19. Kuijlen JM, Mooij JJ, Platteel I, et al. TRAI. L-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006;78:161-171. (Pubitemid 44339684)
20. Reed JC. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 1996; Oct (97):72-100.
21. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35:399-407.
22. Huppertz B, Frank HG, Kaufmann P. The apoptosis cascade - Morphological and immunohistochemical methods for its visualization. Anat Embryol (Berl) 1999;200:1-18. (Pubitemid 29261621)
23. Mitteldorf CA, Alves VA, Kanamura CT, Carneiro PC. Immunocytochemistry applied to aspiration biopsy cytology. Diagnostic contribution in 100 cases of previously stained, routine specimens. Acta Cytol 1999;43:218-226.
24. Wang X, Rao MS, Yeldandi AV. Immunohistochemical analysis of p53 mutations in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Mod Pathol 1995;8:919-923.
25. Saleh HA, Haapaniemi J, Khatib G, Sakr W. Bronchioloalveolar carcinoma: Diagnostic pitfalls and immunocytochemical contribution. Diagn Cytopathol 1998;18:301-306.
26. Athanassiadou P, Dosios T, Petrakakou E, Liossi A, Zerva C, Athanassiades P. p53 and bcl-2 protein expression in non-small-cell lung carcinoma. Diagn Cytopathol 1998;19:255-259.
27. Zudaire I, Lozano MD, Vazquez MF, et al. Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histol Histopathol 2008;23:33-40.
28. Binks S, Clelland CA, Ronan J, Bell J. p53 gene product expression in resected non-small cell carcinoma of the lung, with studies of concurrent cytological preparations and microwave antigen retrieval. J Clin Pathol 1997;50:320-323. (Pubitemid 27208251)
29. Bozzetti C, Franciosi V, Crafa P, et al. Biological variables in non-small cell lung cancer: Comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer 2000;29:33-41. (Pubitemid 30398557)
30. Bozzetti C, Nizzoli R, Guazzi A, et al. Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. Lung Cancer 2002;35:243-247. (Pubitemid 34158656)
31. Kalogeraki A, Kozoni V, Zoras O, et al. Bcl-2 expression as an apoptotic index in non small cell lung carcinomas. In Vivo 2001;15:53-56. (Pubitemid 32248997)
32. Gregorc V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2003;39:41-48.
33. Gregorc V, Darwish S, Ludovini V, et al. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer 2003;42:275-281.
34. Ludovini V, Gregorc V, Pistola L, et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2004;46:77-85.
35. Dowsett M, Detre S, Ormerod MG, et al. Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas. Cytometry 1998;32:291-300.
36. Nijhawan R, Hemachandran M, Joshi K. Apoptosis in breast cancer. Acta Cytol 2003;47:193-196.
37. Milentijevic MJ, Ilic R, Milentijevic I. Cytological grading of breast carcinoma with histological correlation. J BUON 2005;10:251-256.
38. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000;6:4610-4617.
39. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-2152.
40. Kalogeraki AM, Antoniou Ch G, Askoxylakis JP, et al. Cell proliferation and DNA fragmentation (apoptosis) on FNABs of breast invasive ductal carcinomas and their relationship to clinicopathological variables and prognosis. In Vivo 2002;16:271-274.
41. Khan N, Rana F, Afroz N, Khan MA. Cytohistomorphological grading of breast carcinoma with special reference to apoptotic rates and lymph node metastasis. Indian J Pathol Microbiol 2007;50:613-618. (Pubitemid 47329015)
42. Troncone G, Zeppa P, Vetrani A, et al. bcl-2 protein in breast cancer cells obtained by fine needle aspiration (FNA): A preliminary report. Cytopathology 1995;6:219-225.
43. Hemachandran M, Nijhawan R, Joshi K. Cytological grading, apoptosis, and Bcl-2 protein expression in breast cancer. Diagn Cytopathol 2002;26:356-359.
44. Kalogeraki A, Garbagnati F, Santinami M, Zoras O. E-cadherin expression on fine needle aspiration biopsies of breast invasive ductal carcinomas and its relationship to clinicopathologic factors. Acta Cytol 2003;47:363-367.
45. Midulla C, Pisani T, De Iorio P, et al. Cytological analysis and immunocytochemical expression of Ki67 and Bcl-2 in breast proliferative lesions. Anticancer Res 2002;22:1341-1345. (Pubitemid 34836197)
46. Makris A, Allred DC, Powles TJ, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997;44:65-74. (Pubitemid 27179770)
47. Bozzetti C, Nizzoli R, Naldi N, et al. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: Correlation with other biologic factors. Cancer 1999;87:224-230. (Pubitemid 29399615)
48. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058-3063.
49. Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res Treat 1999;53:51-59.
50. Rao JY, Apple SK, Hemstreet GP, Jin Y, Nieberg RK. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: Quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev 1998;7:1027-1033. (Pubitemid 28514104)
51. Koutselini H, Malliri A, Field JK, Spandidos DA. p53 expression in cytologic specimens from benign and malignant breast lesions. Anticancer Res 1991;11:1415-1419.
52. Fabian CJ, Zalles C, Kamel S, et al. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem Suppl 1993;17G:153-160.
53. Fabian CJ, Kamel S, Zalles C, Kimler BF. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem Suppl 1996;25:112-122. (Pubitemid 27078320)
54. Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF. Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials. J Cell Biochem Suppl 1997;28/29:101-110. (Pubitemid 28246633)
55. Kimler BF, Fabian CJ, Wallace DD. Breast cancer chemoprevention trials using the fine-needle aspiration model. J Cell Biochem Suppl 2000;34:7-12.
56. Pelosi G, Bresaola E, Rodella S, et al. Expression of proliferating cell nuclear antigen. Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: An immunochemical study with clinical, pathobiological, and histologic correlations Diagn Cytopathol 1994;11:131-140.
57. Colecchia M, Frigo B, Zucchi A, Leopardi O. p53 protein expression in fine-needle aspirates of breast cancer: an immunocytochemical assay for identifying high-grade ductal carcinomas. Diagn Cytopathol 1995;13:128-132; discussion132-133.
58. Pinder SE, Wencyk PM, Naylor HE, et al. The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: Method, preliminary results and prognostic associations. Cytopathology 1995;6:316-324.
59. Tiniakos DG, Robinson KB, Greenwood H, et al. c-erb B-2 and p53 expression in breast cancer fine needle aspirates. Cytopathology 1996;7:178-186. (Pubitemid 26186806)
60. Kalogeraki A, Panayiotides J, Tamiolakis D, et al. P53 expression in patients with malignant and benign breast diseases. Anticancer Res 2000;20:1801-1805.
61. Malle D, Patakiouta F, Bousoulegas A, Karakitsos P, Destouni C. Image analysis (DNA ploidy) and expression of c-erb B-2 and p53 in imprint smears of breast cancer. Eur J Gynaecol Oncol 2003;24:531-534.
62. Shabalova IP, Chemeris GJ, Ermilova VD, Rodionova LM, Pavlikova NA, Syrjanen KJ. Phyllodes tumour: Cytologic and histologic presentation of 22 cases, and immunohistochemical demonstration of p53. Cytopathology 1997;8:177-187.
63. Howes GP, Stephenson J, Humphreys S. Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast. J Clin Pathol 1996;49:570-573.
64. Gudlaugsdottir S, Sigurdardottir V, Snorradottir M, Jonasson JG, Ogmundsdottir H, Eyfjord JE. P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol 2000;22:268-274. (Pubitemid 30220198)
65. Ball HM, Hupp TR, Ziyaie D, Purdie CA, Kernohan NM, Thompson AM. Differential p53 protein expression in breast cancer fine needle aspirates: The potential for in vivo monitoring. Br J Cancer 2001;85:1102-1105. (Pubitemid 33052306)
66. Lavarino C, Corletto V, Mezzelani A, et al. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer 1998;77:125-130. (Pubitemid 28029784)
67. Baak JP, Gudlaugsson E, Skaland I, et al. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 2009;115:241-254.
68. Biscotti CV, Gero MA, Toddy SM, Fischler DF, Easley KA. Endocervical adenocarcinoma in situ: An analysis of cellular features. Diagn Cytopathol 1997;17:326-332.
69. Selvaggi SM. Cytologic features of high-grade squamous intraepithelial lesions involving endocervical glands on ThinPrep cytology. Diagn Cytopathol 2002;26:181-185.
70. Choo KB, Chong KY. Absence of mutation in the p53 and the retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 1993;193:1042-1046. (Pubitemid 223052373)
71. Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217.
72. Pillai MR, Halabi S, McKalip A, et al. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1996;5:329-335. (Pubitemid 26139114)
73. Sato S, Ito K, Jiko K, Konno R, Yajima A, Sasano H. Cytologic application of p53 overexpression using immunocytochemistry and confocal laser scanning microscopy. Acta Cytol 1998;42:342-345.
74. Athanassiadou P, Petrakakou E, Liossi A, et al. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytol 1999;43:1039-1044.
75. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study. Int J Gynecol Cancer 2007;17:697-704.
76. dos Santos Oliveira Ldo H, Fernandez Ade P, Xavier BL, Machado Rodrigues Ede V, Cavalcanti SM. Analysis of the p53 gene and papillomavirus detection in smears from cervical lesions. Sao Paulo Med J 2002;120:20-22.
77. Athanassiadou P, Petrakakou E, Sakelariou V, et al. Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours. Eur J Cancer Prev 1998;7:225-231. (Pubitemid 28318343)
78. Maacke H, Kessler A, Schmiegel W, et al. Overexpression of p53 protein during pancreatitis. Br J Cancer 1997;75:1501-1504.
79. Pindzola JA, Kovatich AJ, Bibbo M. p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma. Acta Cytol 2000;44:31-36.
80. Itoi T, Takei K, Sofuni A, et al. Immunohistochemical analysis of p53 and MIB-1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 2005;13:229-234.
81. Awadallah NS, Shroyer KR, Langer DA, et al. Detection of B7-H4 and p53 in pancreatic cancer: Potential role as a cytological diagnostic adjunct. Pancreas 2008;36:200-206.
82. Salek C, Benesova L, Zavoral M, et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007;13:3714-3720. (Pubitemid 47202169)
83. Meara RS, Cangiarella J, Simsir A, Horton D, Eltoum I, Chhieng DC. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2. Ki-67 and p53. Cytopathology 2007;18:283-289. (Pubitemid 47476155)
84. Zeppa P, Benincasa G, Fulciniti F, et al. Apoptosis and cytologic differentiation in hepatocellular carcinoma on fine needle aspiration samples. Acta Cytol 1996;40:861-866.
85. Munoz de Toro M, Maffini MV, Giardina RH, Luque EH. Processing fine needle aspirates of prostate carcinomas for standard immunocytochemical studies and in situ apoptosis detection. Pathol Res Pract 1998;194:631-636.
86. Maffini MV, Ortega HH, Stoker C, Giardina RH, Luque EH, Munoz de Toro MM. Bcl-2 correlates with tumor ploidy and nuclear morphology in early stage prostate carcinoma. A fine needle aspiration biopsy study. Pathol Res Pract 2001;197:487-492.
87. Caraway NP, Fanning CV, Shin HJ, Amato RJ. Metastatic small-cell carcinoma of the prostate diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol 1998;19:12-16. (Pubitemid 28303340)
88. Righi E, Rossi G, Ferrari G, et al. Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol 1997;17:436-439.
89. Moreno Sierra J, Luengo Alpuente S, Lopez Garcia-Asenjo J, et al. [Usefulness of P53 oncoprotein in urinary wash cytology: Experience in patients with superficial bladder carcinoma]. Arch Esp Urol 1999;52:943-954.
90. Girgis S, Ramzy I, Baer SC, Schwartz MR. Fine needle aspiration diagnosis of transitional cell carcinoma metastatic to the brain. A case report. Acta Cytol 1999;43:235-238. (Pubitemid 29144720)
91. Dowell SP, Wilson PO, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res 1994;54:2914-2918. (Pubitemid 24187772)
92. Andrikoula M, Vartholomatos G, Tsangaris GT, Bafa M, Tzortzatou- Stathopoulou F, Tsatsoulis A. Fas and Bcl-2 protein expression in thyrocytes of patients with nodular goiter. Eur J Endocrinol 2001;145:403-407. (Pubitemid 32927065)
93. Novosel I, Bulimbasic S, Ramljak V, Matkovic B, Dosen D, Separovic V. [p53, bcl-2 and Ki-67 in the diagnosis of insular thyroid gland cancer. Case report with a review of literature]. Lijec Vjesn 2006;128:264-267.
94. Abati A, Sanjuan X, Wilder A, Linehan WM, Hewitt SM, Merino MJ. Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. Cancer 1999;87:231-237.
95. Ogden GR, Cowpe JG, Chisholm DM, Lane DP. p53 immunostaining as a marker for oral cancer in diagnostic cytopathology-Preliminary report. Cytopathology 1994;5:47-53.
96. Nasuti JF, Braccia MG, Roberts S, Baloch ZW. Utility of cytomorphologic criteria and p53 immunolocalization in distinguishing benign from malignant cystic squamous-lined lesions of the neck on fine-needle aspiration. Diagn Cytopathol 2002;27:10-14.
97. Saqi A, McGrath CM, Skovronsky D, Yu GH. Cytomorphologic features of fine-needle aspiration of metastatic and recurrent melanoma. Diagn Cytopathol 2002;27:286-290.
98. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000;143:307-312. (Pubitemid 30650397)
99. Sviatoha V, Rundgren A, Tani E, Hansson J, Kleina R, Skoog L. Expression of CD40. CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma Cytopathology 2002;13:11-21.
100. Nakamura S, Nagano I, Yoshioka M, et al. Immunocytochemical detection of tumor necrosis factor-alpha in infiltrating tumor cells in the cerebrospinal fluid from five patients with leptomeningeal carcinomatosis. Acta Neurol Scand 1995;91:137-140.
101. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE. Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol 2005;18:1618-1622. (Pubitemid 41670662)
102. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med 2008;132:23-28.
103. Kleinberg L, Lie AK, Florenes VA, Nesland JM, Davidson B. Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma. Hum Pathol 2007;38:986-994. (Pubitemid 46899149)
104. Kleinberg L, Florenes VA, Silins I, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 2007;109:228-238. (Pubitemid 46106237)
105. Harlozinska A, Bar JK, Sedlaczek P, Gerber J. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology. Am J Clin Pathol 1996;105:334-340. (Pubitemid 26077375)
106. Bar JK, Grelewski P, Popiela A, Noga L, Rabczynski J. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: Correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol 2004;95:23-31.
107. Dutta T, Sharma H, Kumar L, et al. Neoadjuvant chemotherapy for epithelial ovarian cancer - Role of apoptosis. Cancer Chemother Pharmacol 2005;56:427-435. (Pubitemid 41095407)
108. Sikora J, Dworacki G, Zeromski J. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions. Nat Immun 1998;16:244-255.
109. Walts AE, Said JW, Koeffler HP. Is immunoreactivity for p53 useful in distinguishing benign from malignant effusions? Localization of p53 gene product in benign mesothelial and adenocarcinoma cells. Mod Pathol 1994;7:462-468.
110. el-Habashi A, el-Morsi B, Freeman SM, el-Didi M, Marrogi AJ. Tumor oncogenic expression in malignant effusions as a possible method to enhance cytologic diagnostic sensitivity. An immunocytochemical study of 87 cases. Am J Clin Pathol 1995;103:206-214.
111. El-Habashi AH, Freeman SM, el-Morsi B, Morris GF, Marrogi AJ. p53 and PCNA coexpression of 81 pleural and peritoneal effusion specimens: An immunohistochemical study. Pathol Res Pract 1996;192:834-839.
112. Tiniakos DG, Healicon RM, Hair T, Wadehra V, Horne CH, Angus B. p53 immunostaining as a marker of malignancy in cytologic preparations of body fluids. Acta Cytol 1995;39:171-176.
113. Mullick SS, Green LK, Ramzy I, et al. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells. Acta Cytol 1996;40:855-860.
114. Lee JS, Lee MC, Park CS, Juhng SW. Diagnostic value of p53 protein and flow cytometric DNA analysis in the study of serous effusions. Acta Cytol 1997;41:1719-1725.
115. Saleh HA, Bober P, Tabaczka P. Improved detection of adenocarcinoma of serous fluids with p53 immunocytochemistry. Acta Cytol 1998;42:1330-1335.
116. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2001;45:18-22.
117. Gong Y, Sun X, Michael CW, Attal S, Williamson BA, Bedrossian CW. Immunocytochemistry of serous effusion specimens: A comparison of ThinPrep vs cell block. Diagn Cytopathol 2003;28:1-5. (Pubitemid 36043475)
118. Mayall F, Cursons R, Jacobson G, Chang B. Single-strand conformational polymorphism (SSCP)-detected p53 gene mutations are a less sensitive marker of malignancy in pleural fluids than p53 immunostaining. Cytopathology 1999;10:259-262. (Pubitemid 29386722)